The Innovative Medicines Initiative (
IMI) is planning a substantial health blockchain project. The breadth of reach extends from the pharma supply chain and clinical trials through to health data. The Blockchain Enabled Healthcare program aims to partner nine big pharma companies with a consortium of stakeholders. In addition to the healthcare community and patients, the consortium will include SME blockchain companies and universities.
The IMI is a public-private partnership between the EU and the European pharmaceutical industry represented by
EFPIA. For the Blockchain Enabled Healthcare program, the IMI is earmarking up to Euro 18m which is expected to last three years.
For any blockchain ecosystem, there’s a need to involve all the relevant stakeholders. Hence the plan to select a consortium to work with the pharma companies. The group is expected to include hospitals, clinics, health authorities, clinical labs, patient representatives as well as universities and SME blockchain companies.
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
Image Copyright: Composite:Ledger Insights, Logos owned by respective companies
